Searchable abstracts of presentations at key conferences in endocrinology

ea0035p6 | Adrenal cortex | ECE2014

An autopsy case of ectopic ACTH-secreting lung carcinoid with Cushing's syndrome

Watanabe Yui , Matoba Keiichiro , Yamazaki Hiroyuki , Tojo Katsuyoshi , Utsunomiya Kazunori

A 81-year-old woman came to our hospital with complaints of reduction in appetite and weakness of lower limbs. She had developed Cushing’s features. Initial laboratory evaluation revealed severe hypokalemia and hyperglycemia without ketoacidosis, and diabetes mellitus had not been detected previously. A series of hormonal assessment revealed marked ACTH-dependent hypercortisolism. Corticotrophin-releasing hormone stimulation test resulted in normal ACTH response, thus we ...

ea0032p671 | Male reproduction | ECE2013

A case of idiopathic hypogonadotropic hypogonadism which attained remission by LH and FSH treatment

Watanabe Yui , Hayashi Takeshi , Yamazaki Hiroyuki , Tojo Katsuyoshi , Utsunomiya Kazunori

A 17-year-old male was referred to our hospital with lack of secondary sex characteristics. His voice didn’t break and he lacked of pubes and hircus. His bilateral testicular volume was small and his sense of smell was normal. There was no varicocele or pituitary adenoma. His chromosomal study showed no aberrations. Serum levels of LH, FSH, total testosterone and free testosterone were 1.05 mIU/ml, 1.68 mIU/ml, 0.26 ng/ml and <0.6 pg/ml respectively. A repeated GnRH t...

ea0056p1139 | Thyroid cancer | ECE2018

Tyrosine kinase inhibitor (TKI) treatment outcome of stage IV-C thyroid differentiated cancer (analyzed by lesion evaluation)

Iwasaki Hiroyuki , Yamazaki Haruhiko , Suganuma Nobuyasu , Sugawara Yuko , Gotoh Naoki , Hatori Shinsuke , Nakayama Hirotaka , Masudo Katsuhiko

Introduction: The standard treatment for differentiated thyroid carcinoma (DTC) with distant metastasis comprises complete total thyroidectomy and lymph node dissection, followed by radioactive iodine (RAI) ablation for metastatic lesions. However, between 2014 and 2015, sorafenib and lenvatinib have been approved for treatment of RAI-refractory advanced thyroid cancer in Japan. We retrospectively analyzed how the treatment results have changed after the approval of tyrosine k...